文献速递肾癌与肾肿瘤

新辅助免疫检查点抑制剂后复杂局部晚期肾细胞癌部分或根治性肾切除术的安全性:一项1b期试验分析

Safety of Partial and Radical Nephrectomy for Complex Locally Advanced Renal Cell Carcinoma After Neo-Adjuvant Immune Checkpoint Inhibition: Analysis From a Phase 1b Trial (Durvalumab +/- Tremelimumab).
PubMed 文献 · Urology · 2025-05-27

OBJECTIVE: To determine the surgical safety after neo-adjuvant durvalumab +/- tremelimumab for patients with locally advanced renal rell carcinoma (RCC).…

要点

  • 新辅助度伐利尤单抗±替西木单抗后肾切除术术中无并发症发生。
  • 术后30天内发生5例Clavien-Dindo 2-3b级并发症,3例再入院。
  • 肿瘤手术复杂,最常见RENAL评分为11xh,6例有肾静脉癌栓。

核心结论

  • 局部晚期肾细胞癌患者接受新辅助度伐利尤单抗±替西木单抗后行肾切除术是安全的。

研究设计与样本

  • 开放标签1b期试验,2016-2020年在两个中心进行,纳入临床分期T2b-4和/或N1、M0、ECOG 0-1的局部晚期肾细胞癌患者。
  • 共评估四个队列:队列1接受度伐利尤单抗单药1次,队列2、2a和3接受度伐利尤单抗联合替西木单抗1次;队列1-2a还接受辅助治疗。

主要发现

  • 肿瘤手术复杂,最常见RENAL评分为11xh,6例患者存在肾静脉癌栓。
  • 中位估计失血量为400cc,3例患者术后需要输血(总共4单位)。
  • 术中无并发症发生,4例(16%)术中发现肾脏周围粘连。
  • 3例患者需要再入院,术后30天内发生5例Clavien-Dindo并发症(2-3b级)。

临床怎么用

  • 对于局部晚期肾细胞癌患者,新辅助度伐利尤单抗±替西木单抗后行部分或根治性肾切除术未增加术中并发症风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the surgical safety after neo-adjuvant durvalumab +/- tremelimumab for patients with locally advanced renal rell carcinoma (RCC). METHODS: An open-label phase 1b trial of neoadjuvant durvalumab +/- tremelimumab in locally advanced RCC was performed at two sites between 2016-2020 (NCT02762006). Inclusion criteria included clinical stage T2b-4 and/or N1, M0 disease, ECOG 0-1, and adequate organ function. A total of four cohorts were evaluated. In the neoadjuvant setting, cohort 1 received durvalumab (D) x 1, and cohorts 2, 2a, and 3 received D + Tremelimumab (T) x 1 dose. Cohorts 1-2a also received adjuvant therapy. Pre- and post-surgical patient characteristics were evaluated and descriptive statistics are presented. RESULTS: Twenty-five patients underwent neo-adjuvant therapy prior to radical/partial nephrectomy and twenty-three received adjuvant therapy after surgery. Tumors were surgically complex with the most common RENAL score being 11xh and renal vein thrombus present in 6 patients. Median estimated blood loss was 400cc with 3 patients requiring postoperative transfusion (4 units total). No intraoperative complications occurred. There was note of intraoperative adhesions near the kidney in 4 cases (16%). Three patients required readmission and 5 Clavien-Dindo complications occurred within 30 days of surgery (2-3b). CONCLUSION: Surgery for locally advanced RCC is safe for patients after neoadjuvant durvalumab +/- tremelimumab.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Scovell JM, Rini BI, Krishnamurthi V, et al. Safety of Partial and Radical Nephrectomy for Complex Locally Advanced Renal Cell Carcinoma After Neo-Adjuvant Immune Checkpoint Inhibition: Analysis From a Phase 1b Trial (Durvalumab +/- Tremelimumab). Urology. 2025. PMID: 40441307. doi:10.1016/j.urology.2025.05.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。